| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = -$30,409 ) |
| | 2022 | 2018 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 003 | 3 | NIH | 9/8/2022 | -$255 |
| | 2022 | 2018 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 005 | 3 | NIH | 9/27/2022 | $255 |
| | 2022 | 2018 | AVIDBIOTICS CORP. | 100 KIMBALL WAY | SOUTH SAN FRANCISCO | CA | 94080-6218 | SAN MATEO | USA | R33AI121692 | Title: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs. | 000 | 3 | NIH | 8/19/2022 | -$30,409 |
|
|
